Pricing Log in Create free account

iSpecimen Inc. (ISPC) vs ProPhase Labs, Inc. (PRPH)

iSpecimen Inc. and ProPhase Labs, Inc. are both Diagnostics & Research companies. iSpecimen Inc. is the larger, with a market value of $2.0M against $1.2M — 1.7× the size. ProPhase Labs, Inc. grew revenue faster over the last twelve months: −43.5% against −92.1%. ProPhase Labs, Inc. has the higher net margin (−717.4% vs −2,449.0%) and the lower return on invested capital (−387.3% vs 0.00%). Across the 17 metrics below, ProPhase Labs, Inc. leads on 12 and iSpecimen Inc. on 5.

Valuation

Metric ISPC PRPH Diagnostics & Research median
P/E n/m n/m 34.52
P/S 2.39 0.04 4.24
P/B 0.64 n/m 3.42
Price to free cash flow n/m n/m 33.51
EV/EBITDA 0.08 n/m 23.44
EV/Sales (1.47) 1.84 5.18
Earnings yield (6,581.25%) (25,845.00%) (1.50%)
Free cash flow yield (973.26%) (3,945.49%) 0.00%

Profitability

Metric ISPC PRPH Diagnostics & Research median
Gross margin (108.26%) 16.38% 48.32%
Operating margin (2,020.05%) (498.73%) (5.68%)
Net margin (2,449.02%) (717.43%) (4.10%)
Free cash flow margin (1,866.61%) (175.22%) 0.00%
Return on equity (968.44%) (543.95%) 0.00%
Return on assets (170.09%) (45.53%) (6.05%)
Return on invested capital 0.00% (387.30%) 0.00%

Growth

Metric ISPC PRPH Diagnostics & Research median
Revenue growth (TTM) (92.11%) (43.52%) 8.99%
EPS growth (last fiscal year) 87.03% 93.33% 20.36%
Revenue growth, 5-year CAGR (25.10%) (21.43%) 7.30%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ISPC PRPH Diagnostics & Research median
Debt to equity 0.00 (1.82) 0.01
Current ratio 0.82 0.05 2.27
Net debt to EBITDA 0.95 (0.74) 0.68

Dividend

Metric ISPC PRPH Diagnostics & Research median
Dividend yield — — 0.67%
Payout ratio — — 0.20

Size

Metric ISPC PRPH Diagnostics & Research median
Market cap 2.03m 1.17m 2.22b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack